Use of pregnancy personalised follow-up in case of maternal social vulnerability to reduce prematurity and neonatal morbidity

Table 2 Pregnancy, labor and neonatal outcomes according to study group

	PPFU Participation
	Yes (N = 686)	No (N = 3272)	p
Pregnancy characteristics
Pregnancy complication^a n (%)	433 (63.1)	2128 (65.0)	0.362
Labor outcomes
Induction of labor n (%)	258 (37.6)	1177 (36.0)	0.443
Delivery mode n (%)
Cesarean section before labor	57 (8.3)	193 (5.9)	0.023
Emergency Cesarean section before labor	28 (4.1)	129 (3.9)	0.95
Cesarean section during labor	77 (11.2)	314 (9.6)	0.22
Post-Partum hemorrhage n (%)	48 (7.0)	214 (6.5)	0.724
Neonatal outcomes
Premature birth (< 37 weeks) n (%)	59 (8.6)	357 (10.9)	0.084
Premature birth (< 34 weeks) n (%)	29 (4.2)	209 (6.4)	0.038
Neonatal intensive care unit admission n (%)	46 (6.7)	318 (9.7)	0.016
5-min Apgar score < 7	18 (2.6)	83 (2.5)	1.000
Cord blood pH < 7.10	24 (3.5)	118 (3.6)	0.980
Small for gestational age^c n (%)	159 (23.2)	671 (20.5)	0.131
Pregnancy outcome n (%)			0.263
Neonatal death	1 (0.1)	1 (0.0)
Miscarriage/abortus	2 (0.3)	17 (0.5)
Medical abortion	2 (0.3)	23 (0.7)
Stillbirth	3 (0.4)	30 (0.9)

PPFU Personalized pregnancy follow-up
^adefined as the occurrence of one or more of the following complications: gestational diabetes, pre-eclampsia, fetal growth restriction, proteinuria, thrombopenia, threatened preterm labor, premature rupture of membranes (PROM), deep vein thrombosis and cholestasis of pregnancy
^bdefined by a cord blood pH < 7.10 and/or a 5-min Apgar score < 7 and/or neonatal intensive care unit admission
^cSmall for gestational was defined by a birthweight < to the 10th percentile according to the WHO fetal growth charts

ISSN: 1471-2393